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Abstract
Standard cytotoxic chemotherapy for Hodgkin Lymphoma (HL) has changed little in 30 years; the treatment for patients
with relapsed or refractory disease remains challenging and novel agents are under development. JAK/STAT constitutive
activation plays an important role in the pathogenesis of HL. Lestaurtinib is an orally bioavailable multikinase inhibitor that
has recently been shown to inhibit JAK2 in myeloproliferative disorders. The potential role of Lestaurtinib in HL therapy is
unknown. We have analyzed the effect of Lestaurtinib treatment in five HL cell lines from refractory patients, L-428, L-1236,
L-540, HDML-2 and HD-MY-Z. At 48 h, a dose-dependent cell growth inhibition (23%–66% at 300 nM) and apoptotic
increment (10%–64% at 300 nM) were observed. Moreover, Lestaurtinib inhibited JAK2, STAT5 and STAT3 phosphorylation
and reduced the mRNA expression of its downstream antiapoptotic target Bcl-xL. In addition, we have analyzed the effect of
Lestaurtinib treatment in lymph nodes from four classic HL patients. We observed a decrease in cell viability at 24 hours of
treatment in three patients (mean decrease of 27% at 300 nM). Our findings provide, for the first time, a molecular rationale
for testing JAK2 inhibitors, specifically Lestaurtinib, in HL patients.
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Introduction
Hodgkin lymphoma (HL) is characterized by the presence of a
small proportion of tumor cells, the Hodgkin/Reed Sternberg
(HRS) cells, surrounded by a specific non-tumor microenviron-
ment. HRS cells usually account for only 1% of cells in the tumor
tissue, and few cell lines have been established from HL patients.
To date, the most frequent genetic alterations in HRS cells involve
members of two main signaling pathways: nuclear factor-kappaB
(NF-kB) and Janus kinase-Signal transducer and activator of
transcription (JAK/STAT) [1].
The JAK2/STAT5 pathway is a common signaling pathway
used by many cytokines that regulate target gene expression
related to cell survival, proliferation, angiogenesis, and immune
evasion [2]. Bcl-xL is an antiapoptotic gene whose expression is
induced by STAT5 DNA binding, and activation of the JAK2/
STAT5 pathway can modulate apoptosis and survival through
Bcl-xL expression [3]. The JAK2/STAT5 pathway plays an active
role in HL, where genomic gains of JAK2 are frequently observed
[4], and where the suppressor of cytokine signaling 1 (SOCS1), a
negative regulator of JAK/STAT signaling, appears mutated and
inactivated [5]. While activating mutations in JAK2 have been
found in myeloproliferative disorders (MPD) [6], the expression of
JAK2 in primary mediastinal large B-cell lymphomas and HL is
not the result of mutations [7], although constitutive activation of
STATs has been observed [8]. Recently, our group has observed a
postranscriptional regulation of JAK2 mediated by a microRNA
(miRNA), miR-135a, whose expression was downregulated in HL
patients [9].
Although HL is considered one of the most curable human
cancers (cure rates of 80–90%) [10], the treatment of patients with
relapsed and refractory disease, especially those who relapse after
autologous stem cell transplantation, remains challenging. The
gold-standard therapy in HL is anthracycline-based, with
doxorubicin, bleomycin, vinblastine and dacarbacine (ABVD)
[11]. HL patients whose disease relapses after stem cell
transplantation are rarely cured with current treatment modalities.
Moreover, no new drugs have been approved for HL by the US
Food and Drug Administration (FDA) in more than 30 years [12].
Thus, new drugs and novel treatment strategies based on our
understanding of HL biology and signaling pathways are needed
to improve outcome for these patients. Several therapeutic targets,
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[4,13]. Novel JAK2 inhibitors have been developed and tested
[14], some of which are now being studied in phase I clinical trials
in HL [15].
Lestaurtinib (formerly known as CEP-701) is a multi-targeted
tyrosine kinase inhibitor which has been shown to potently inhibit
FLT3 at nanomolar concentrations in preclinical studies, leading
to its rapid development as a potential targeted agent in acute
myeloid leukemia [16]. Moreover, recent studies have further
shown that Lestaurtinib inhibitory activity is not limited to FLT3
and can suppress JAK2/STAT5 signaling through specific JAK2
inhibition [17]. In order to elucidate the potential role of
Lestaurtinib in HL, we have analyzed the in vitro effectiveness of
Lestaurtinib in five HL cell lines from refractory patients and its
role in the JAK2/STAT5 signaling pathway. In addition, we have
analyzed for the first time the effect of Lestaurtinib in lymph nodes
from classic HL patients by flow cytometry.
Materials and Methods
Cell culture and treatment
Five HL cell lines, L-428, L-1236, L-540, HDLM-2 and HD-
MY-Z (DSMZ - the German Resource Centre for Biological
Material) were assayed for proliferation and apoptosis after
treatment with Lestaurtinib (CEP-701 hydrate, Sigma-Aldrich,
St. Louis, MO) or DMSO (Sigma-Aldrich). L-428, L-1236 and
HDMYZ cell lines, were cultured in RPMI 1640 containing 10%
fetal calf serum (Invitrogen, Paisley, UK); the L-540 and HDLM2
cell lines were cultured in RPMI 1640 containing 20% fetal calf
serum (Invitrogen). For proliferation and apoptosis analyses, cells
(1610
5 cells/well) were plated in a 96-well plate in culture medium
in the presence of 30, 50, 70, 100, 150, 200 or 300 nM
Lestaurtinib or no drug/DMSO vehicle control. In addition, in
order to compare the effect of Lestaurtinib with doxorubicin, a
component of standard HL therapy, we performed a proliferation
analysis in cells treated with 300 nM of doxorubicin. For protein
analysis, cells (1.5610
6 cells/well) were plated in a 12-well plate
and treated with 30, 100 or 300 nM Lestaurtinib or 300 nM
DMSO. All cells were treated with a unique dose at the start of the
experiment, after which the medium was not modified or replaced.
Proliferation and apoptosis assays
Cell growth was determined by the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (MTS) (Promega, Madison, WI).
At 48 h after treatment with Lestaurtinib or DMSO, MTS reagent
was added and cells were incubated for 30–60 mins at 37uC. Cell
proliferation was measured by OD 490 nm using a VersaMax
microplate reader (Molecular Devices, Silicon Valley, CA).
Caspase 3/7 activity was directly measured at 48 h after
treatment using a CaspaseGlo 3/7 kit (Promega) as per the
manufacturer’s protocol. At 48 h after treatment with Lestaurtinib
or DMSO, CaspaseGlo reagent was added and cells were
incubated for 1 hour at room temperature in the dark. Relative
light intensity was measured in each well using an Orion II
Microplate luminometer (Berthold Detection Systems, Black
Forest, Germany).
Western Blot analysis
Total protein was isolated using Qiagen Qproteome Mamma-
lian Protein Prep Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol. Equal amounts of proteins (50 mg)
were separated by SDS-polyacrylamide electrophoresis in 10%
Tris-HCl polyacrylamide gels and transferred to pure nitrocel-
lulose membranes (Trans-Blot Transfer Medium, Bio-Rad,
Hercules, CA). Membranes were incubated with antibodies
against JAK2 (Upstate, Millipore, Billerica, MA), phospho-
JAK2 (Tyr1007/1008), phospho-STAT5 (Tyr694) and phos-
pho-STAT3 (Tyr705) (Cell Signaling, Danvers, MA), STAT5
and STAT3 (Santa Cruz Biotechonology, Santa Cruz, CA) and
a ´-tubulin (Sigma) as control. Antibody binding was revealed by
incubation with anti-mouse (Sigma) or anti-rabbit (Santa Cruz
Biotechnology) IgG peroxidase conjugate secondary antibodies.
Chemiluminescence was detected using SuperSignal West Pico
Chemiluminescent Substrate (Pierce Biotechnology, Rockford,
IL) and read in Chemidoc System (Bio-Rad). The protein density
of the bands was quantified using Quantity One software v 4.2.6,
and relative quantification was calculated with reference to the a ´-
tubulin signal.
Bcl-xL mRNA analysis
RNA was extracted from the cell lines using Trizol total RNA
isolation reagent (Invitrogen, Carlsbad, CA) as per the manufac-
turer’s protocol. Total cDNA was synthesized from total RNA
using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA) as per the manufacturer’s
protocol. Polymerase chain reaction (PCR) was performed using
TaqMan Gene Expression assays (Applied Biosystems) for BCL-xL
(Hs99999146_m1) and GUSB (Hs99999908_m1), used as endog-
enous control.
Patient lymph node analysis
A cell suspension was made from cryopreserved (freezing
medium based on RPMI 30%, FBS 60% and DMSO 10%), newly
diagnosed lymph node samples from four classic HL patients
diagnosed at the Hematology Department of the University
Hospital del Mar, Barcelona, Spain (Table 1). The study was
approved by the local Ethics Committee and informed consent
was provided according to the Declaration of Helsinki.
The viability of the lymph node cells was at least 87% at the
initiation of cell culture, as assessed by Tripan Blue (Invitrogen).
We performed a cell viability analysis of lymph node cells and
found that viability was 59.9% at baseline, 41.8% at 24 h, and
30.6% at 48 h (Figure S3). Based on these results, we evaluated by
flow cytometry 750,000 cells cultured for 24 hours with 300 nM of
Lestaurtinib or DMSO. HRS cells were gated by the expression of
CD40-PE-Cy5, CD95-Pacific Blue and CD30-PE, and the
absence of CD3-APC-Cy7. Antibodies and control isotypes were
Table 1. Clinical and biological characteristics of HL patients.
Characteristic P1 P2 P3 P4
Age 24 30 28 43
Sex Female Male Male Female
Histology Classic HL,
Nodular
sclerosis
Classic
HL*
Classic HL,
Lymphocyte-rich
Classic HL,
Nodular
sclerosis
EBV 22 2 2
CD30 ++ + +
CD15 ++ + +
CD20 22 2 2
Stage IIA IIIA IIIA IIA
*Unknown histologic subtype.
doi:10.1371/journal.pone.0018856.t001
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(San Diego, CA) [18,19]. Viability was analyzed by the presence of
the membrane phospholipid phosphatidylserine on the outer
leaflet of the plasma membrane, using FITC Annexin V (BD
Bioscience). In order to obtain an accurate count, we added the
same number of CountBright
TM absolute counting beads
(Invitrogen) to each sample. Samples were analyzed on a FACS
CANTO II (Becton Dickinson) and 200,000 events were collected.
Statistical analysis
Means were compared between 2 groups using a 2-sided
Student t-test, using GraphPad Prism 5 (GraphPad Software, Inc.,
La Jolla, CA). The proliferation and apoptosis data were shown as
mean 6 SEM of three independent replicates.
Results and Discussion
Although HL is a highly curable disease, advanced HL has
typically been associated with high failure rates [20] and relapsed
or refractory HL constitutes a common problem [21,22]; new
drugs are thus needed for these groups of patients. In the present
study, we analyzed the in vitro activity of Lestaurtinib, which has
recently been shown to be a multikinase inhibitor that targets both
wild-type and mutated JAK2 in MPD [16].
Proliferation and apoptosis in response to Lestaurtinib of
cultured HL cells was evaluated in all HL cell lines after 48 h of
treatment and compared to cells treated with DMSO vehicle
control (normalized to 100%). Reduction of proliferation of HL
cells reached the lowest level at 100 nM of Lestaurtinib and
remained constant thereafter (Figure 1A). At 300 nM of
Lestaurtinib, a 38% reduction in proliferation was observed in
L-428, 60% in L-1236, 66% in L-540, 23% in HDLM-2 and 23%
in HD-MY-Z cell lines. At 300 nM of doxorubicin, the reduction
in proliferation was 20.3% in L-428, 18.7% in L-1236, 54% in L-
540, 34.5% in HDLM-2, and 19% in HD-MY-Z cell lines. At
300 nM, apoptosis increased 62% in L-428, 57% in L-1236, 10%
in L-540, 64% in HDLM-2 and 30% in HD-MY-Z (Figure 1B). In
order to determine whether Lestaurtinib inhibition had a transient
or a long-lasting effect on cell growth, we then looked at the effect
at different incubation times (24, 48, 72 and 96 h). We observed
no significant differences between 48, 72 or 96 hours (Figure S1).
Proliferation and apoptosis were both Lestaurtinib dose-
dependent. Since DMSO is toxic at doses of 5 mM, it was
impossible to determine the dose at which 100% of the cells were
killed. However, 50% of the cells had died at 1 mM in L-428 and
at 300 nM in L-1236 and L-540, while, in HDLM-2 and HD-MY-
Z, about 45% and 42% of cells, respectively, had died at 4 mM
(Figure S2).
The JAK/STAT pathway is one of the most frequently altered
pathways in HL. In addition to genomic gains of JAK2 [4],
particularly due to 9p24 gains [23], SOCS1, a negative regulator
of JAK/STAT signaling, is often somatically mutated and
inactivated [5]. Moreover, constitutive activation of STAT3 has
been reported in HL cell lines [8]. In order to investigate the effect
of Lestaurtinib treatment on the JAK2 pathway, we assessed the
levels and the phosphorylation state of JAK2 and its downstream
target molecules following Lestaurtinib treatment. After 1 h,
phospho-JAK2 levels had decreased in all the HL cell lines by
46–94% at 300 nM, although no significant changes were
observed in JAK2 total protein expression (Figure 2). To assess
Figure 1. Proliferation (A) and apoptosis (B) analysis after 48 h of Lestaurtinib treatment in L-428, L-1236, L-540, HDLM-2 and HD-
MY-Z cell lines. The data are shown as mean 6 SEM of three independent replicates. *p,0.05; **p,0.01; ***p,0.001.
doi:10.1371/journal.pone.0018856.g001
Figure 2. Western blot analysis of JAK2/STAT5 pathway protein levels in L-428, L-1236, L-540, HDLM-2 and HD-MY-Z cells after 1 h
of Lestaurtinib treatment at different doses: 30, 100 and 300 nM.
doi:10.1371/journal.pone.0018856.g002
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inhibition on the JAK2/STAT5 signaling pathway, protein levels
of STAT5, phospho-STAT5, STAT3 and phospho-STAT3 were
then analyzed (Figure 2). Lestaurtinib significantly inhibited
phosphorylation of STAT5 and STAT3, but with no significant
changes in STAT5 and STAT3 total protein. Following 1 hour of
300 nM of Lestaurtinib treatment, phospho-STAT5 and phospho-
STAT3 levels decreased by 88–100% and by 97–100%,
respectively (Figure 2).
Bcl-xL is a prosurvival protein induced by phosphorylated
STAT5 DNA binding. It appears upregulated in some hemato-
logic malignancies [24] and in primary HL samples [25] and is
involved in apoptotic resistance in HRS cells [25]. Decreased
phosphorylation of STAT5 resulted in decreased mRNA expres-
sion of its downstream antiapoptotic effector Bcl-xL. After 1 h of
300 nM of Lestaurtinib treatment, Bcl-xL mRNA expression
levels had decreased by 52% in L-428, 28% in L-1236, 37% in L-
540, 55% in HDLM-2 and 71% in HD-MY-Z (Figure 3). This
Figure 3. Bcl-xL mRNA analysis after 1 h of Lestaurtinib treatment in L-428, L-1236, L-540, HDLM-2 and HD-MY-Z cell lines.
doi:10.1371/journal.pone.0018856.g003
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Lestaurtinib [26].
Additionally, we have analyzed the effect of Lestaurtinib in
lymph nodes from four classic HL patients. Fromm et al.
demonstrated that HL cells from a lymph node can be detected
[19] and sorted by flow cytometry [18]. In the present study, we
have evaluated the effect of treatment with 300 nM of Lestaurtinib
in the subpopulation of lymph node cells CD30+, CD40+, CD95+
and CD3-, which contain HL cells [18,19] (Figure 4A).
After 24 h, cell viability had decreased in three of the four
cases by 22%, 35% and 24% versus control cells (DMSO)
(Figure 4B). In the patient 3 (non-responder), we increased the
treatment dose to 1 mM and then we observed a reduction in cell
viability by 12% (SEM 6 2,3%). This patient has a different
histological subtype (lymphocyte-rich) than cell lines (nodular
sclerosis and mixed cellularity), and this could explain the
different treatment response. In order to shed light on the
potential toxicity of Lestaurtinib, we have also analyzed cell
viability in lymph node CD3+ cells after treatment with 300 nM
of Lestaurtinib and observed no decrease of viability (mean versus
control=100.5%; range: 90%–119%).
The present study is the first of its kind to analyze treatment of
HL in patient lymph nodes by flow cytometry. Although our
results cannot be conclusive due to our small sample size, they
provide the first hints that Lestaurtinib induces growth inhibition
and apoptosis activation in HL cells through dysregulation of the
JAK2/STAT5 signaling pathway. If our findings are confirmed in
a larger patient population, they could provide a molecular
rationale for considering treatment with Lestaurtinib for HL
patients with relapsed/refractory disease.
Figure 4. Analysis of cell viability after 24 h of Lestaurtinib treatment in four lymph nodes from classic HL patients. A: representative
example of population selected for analysis (anexin-negative, CD32, CD40+, CD30+ and CD95+). B: cell viability after treatment compared to DMSO
control. The data are shown as mean 6 SEM of two independent replicates. SEM was calculated on the proportion (treated/untreated cells).
doi:10.1371/journal.pone.0018856.g004
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Figure S1 Proliferation analysis after 24 h, 48 h, 72 h and 96 h
of Lestaurtinib treatment in L-428, L-1236, L-540, HDLM-2 and
HD-MY-Z cell lines. The data are shown as mean 6 SEM of
three independent replicates.
(TIF)
Figure S2 Proliferation analysis after 48 h of Lestaurtinib
treatment at increasing doses up to 4 mM in L-428, L-1236, L-
540, HDLM-2 and HD-MY-Z cell lines. The data are shown as
mean 6 SEM of three independent replicates.
(TIF)
Figure S3 Cell viability analysis (negative Annexin V) of lymph
node cells cultured up to 48 h with growth media (RPMI1640 with
10% FBS).
(TIF)
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